JP2016534023A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534023A5
JP2016534023A5 JP2016515409A JP2016515409A JP2016534023A5 JP 2016534023 A5 JP2016534023 A5 JP 2016534023A5 JP 2016515409 A JP2016515409 A JP 2016515409A JP 2016515409 A JP2016515409 A JP 2016515409A JP 2016534023 A5 JP2016534023 A5 JP 2016534023A5
Authority
JP
Japan
Prior art keywords
hydroxy
propan
pyrrolidin
oxoacetamide
dioxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016515409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534023A (ja
JP6537500B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/056555 external-priority patent/WO2015042397A1/en
Publication of JP2016534023A publication Critical patent/JP2016534023A/ja
Publication of JP2016534023A5 publication Critical patent/JP2016534023A5/ja
Application granted granted Critical
Publication of JP6537500B2 publication Critical patent/JP6537500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016515409A 2013-09-20 2014-09-19 疾患治療用のグルコシルセラミドシンターゼ阻害剤 Active JP6537500B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361880752P 2013-09-20 2013-09-20
US61/880,752 2013-09-20
PCT/US2014/056555 WO2015042397A1 (en) 2013-09-20 2014-09-19 Glucosylceramide synthase inhibitors for the treatment of diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019104161A Division JP2019182869A (ja) 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2016534023A JP2016534023A (ja) 2016-11-04
JP2016534023A5 true JP2016534023A5 (enExample) 2017-11-02
JP6537500B2 JP6537500B2 (ja) 2019-07-03

Family

ID=51794951

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016515409A Active JP6537500B2 (ja) 2013-09-20 2014-09-19 疾患治療用のグルコシルセラミドシンターゼ阻害剤
JP2019104161A Pending JP2019182869A (ja) 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019104161A Pending JP2019182869A (ja) 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Country Status (10)

Country Link
US (2) US10227323B2 (enExample)
EP (2) EP3046920B1 (enExample)
JP (2) JP6537500B2 (enExample)
CN (2) CN110372636B (enExample)
AU (2) AU2014321397C1 (enExample)
CA (1) CA2924545C (enExample)
IL (2) IL244628B (enExample)
MX (1) MX374452B (enExample)
TW (2) TWI690511B (enExample)
WO (1) WO2015042397A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014321397C1 (en) * 2013-09-20 2019-08-01 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
US11744396B1 (en) * 2015-11-10 2023-09-05 Caffeine Innovations, LLC System, method, and device for agitating coffee grounds
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
CN107216238A (zh) * 2016-03-21 2017-09-29 湖南师范大学 醇镁法制备4-甲基儿茶酚
JP6633814B2 (ja) * 2016-09-02 2020-01-22 アイジーエム グループ ビー.ヴィ. 光開始剤としての多環式グリオキシレート
US20190322676A1 (en) * 2016-12-20 2019-10-24 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
EP3680241A1 (en) 2017-03-20 2020-07-15 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
BR112019020277B1 (pt) 2017-03-28 2023-02-14 Basf Se Compostos, composição, método para combater ou controlar pragas de invertebrados, método para proteger plantas em crescimento, semente tratada, usos de um composto da fórmula i
MX2020006566A (es) 2017-12-21 2020-09-25 Basf Se Compuestos plaguicidas.
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
CN111393405B (zh) * 2019-01-02 2022-11-25 中国科学院上海药物研究所 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用
TW202525783A (zh) * 2019-07-01 2025-07-01 美商古拉森療法公司 β腎上腺素激動劑及其使用方法
JP7539382B2 (ja) * 2019-07-29 2024-08-23 武田薬品工業株式会社 複素環化合物
HUE072832T2 (hu) 2019-09-19 2025-12-28 Novo Nordisk Healthcare Ag Piruvát kináz R-t (PKR) aktiváló készítmények
US11220479B2 (en) * 2019-10-23 2022-01-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
BR112022009409A2 (pt) 2019-11-15 2022-08-09 Yuhan Corp Novos derivados que têm grupamento 2,3-dihidro-1h-indeno ou 2,3-dihidrobenzofurano ou sal farmaceuticamente aceitável dos mesmos e composições farmacêuticas que os compreendem
US20230002380A1 (en) * 2019-11-15 2023-01-05 Yuhan Corporation Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
EP4142878B1 (en) * 2020-04-28 2024-06-26 The Regents of The University of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
CN114621140B (zh) * 2020-12-10 2023-08-11 中国科学院上海药物研究所 芳基二氟乙酰胺化合物及其制备方法和用途
CN112457277B (zh) * 2020-12-16 2022-06-28 西安国康瑞金制药有限公司 一种他氟前列腺素的制备方法
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113912544B (zh) * 2021-11-29 2023-03-17 沧州普瑞东方科技有限公司 一种5-溴-1-甲基吲唑的制备方法
CN120129680A (zh) * 2022-08-18 2025-06-10 艾司林科生物医药有限公司 葡糖神经酰胺合酶抑制剂的晶型及其用途
CN115433157B (zh) * 2022-11-09 2023-02-07 苏州凯瑞医药科技有限公司 一种依利格鲁司特中间体的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
AU5267900A (en) 1999-05-07 2000-11-21 Texas Biotechnology Corporation Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
US20020156063A1 (en) 2001-04-06 2002-10-24 Setti Eduardo L. Arylacetamido-ketobenzoxazole as cysteine protease inhibitors
PT2266968E (pt) 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
WO2003045928A1 (en) 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
JPWO2003057874A1 (ja) 2001-12-28 2005-05-19 住友製薬株式会社 腎疾患の疾患マーカー及びその利用
WO2004080960A2 (en) 2003-03-06 2004-09-23 Neose Technologies Inc. Methods and compositions for the enzymatic synthesis of gangliosides
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
GEP20104906B (en) * 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
JP2008519840A (ja) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
US20090088433A1 (en) 2005-01-26 2009-04-02 Bertrand Leblond Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2007134086A2 (en) 2006-05-09 2007-11-22 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
WO2008011487A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2008011483A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
US20100105687A1 (en) 2007-03-06 2010-04-29 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
EP2594562B1 (en) * 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
KR101640263B1 (ko) * 2007-10-05 2016-07-15 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
CL2008003120A1 (es) 2007-11-01 2009-10-09 Acucela Inc Compuestos derivados de fenilalquil-, fenilalquenil-, fenilalquinil- amina, feniltioalquilamina, fenilaminoalquilamina, fenilalcoxiamina y fenilalquilguanidina; composicion farmaceutica; y uso de los compuestos para tratar un trastorno o enfermedad oftalmologica tal como retinopatia, maculopatia, retinitis pigmentosa, uveitis, entre otras.
WO2009099736A2 (en) * 2008-02-06 2009-08-13 Lead Therapeutics, Inc. Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
JP2011529500A (ja) * 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
GB0817576D0 (en) 2008-09-25 2008-11-05 Lectus Therapeutics Ltd Calcium ion channel modulators & uses thereof
US8309593B2 (en) * 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
SG10201407881WA (en) * 2009-11-27 2015-01-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
US20110144081A1 (en) * 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
WO2013059119A1 (en) * 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CA2906396A1 (en) * 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
AU2014321397C1 (en) * 2013-09-20 2019-08-01 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases

Similar Documents

Publication Publication Date Title
JP2019182869A5 (enExample)
US10913727B2 (en) Modulators of the integrated stress pathway
TWI432431B (zh) 調控c-fms及/或c-kit活性之化合物及其用途
JP6385954B2 (ja) キナーゼ調節のための化合物および方法、ならびにその適応
JP4310109B2 (ja) ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
Peifer et al. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1 H-indole-3yl)-1, 5-dihydro-2 H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors
US11155557B2 (en) Pyrazolopyrimidine compounds and methods of use thereof
KR20200136425A (ko) 옥사진 모노아실글리세롤 리파아제(magl) 억제제
IL303196B1 (en) Heteroaryl substituted pyridines and methods of use
JP2016517878A5 (enExample)
JP2021533093A (ja) モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物
RU2019132212A (ru) Селективные ингибиторы hdac6
TW201718597A (zh) Hpk1抑制劑及其使用方法
JP7744350B2 (ja) 置換ピラゾロ-ピリミジンおよびその使用
BG108013A (bg) Заместени аминопроизводни и методи за използването им
TW201437206A (zh) TrK阻礙化合物
NZ630124A (en) Estrogen receptor modulators and uses thereof
ES2342783T3 (es) Aril aciltioureas sustituidas y compuestos relacionados, inhibidores de la replicacion viral.
JP2017512786A (ja) TrkAキナーゼ阻害薬、その組成物および方法
MX2014013011A (es) Compuesto heterociclico nitrogenado.
KR20170094263A (ko) Nadph 옥시다제 억제제인 아미도 티아디아졸 유도체
JP2017530185A5 (enExample)
KR20140041609A (ko) 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체
JP2016535051A5 (enExample)
JP2011510985A5 (enExample)